Clostridium difficile-associated diarrhea in radiooncology: an underestimated problem for the feasibility of the radiooncological treatment?

Radiation Oncology

Oliver Kölbl¹  Matthias Hipp¹  Matthias G Hautmann¹ 

[1] Institutional address: Department of Radiotherapy, University of Regensburg, Regensburg, Germany

关键词: Chemoradiation;    Radiation Therapy;    Radiotherapy;    Colitis;    Diarrhea;    Clostridium difficile;    Clostridium difficile-associated diarrhea;   

Others  :  1223926
DOI  :  10.1186/1748-717X-6-89

 received in 2011-04-05, accepted in 2011-08-01,  发布年份 2011

【 授权许可】

   
2011 Hautmann et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Vaishnavi C: Clinical spectrum & pathogenesis of Clostridium difficile associated diseases. Indian J Med Res 2010, 131:487-499.
• [2]Hookman P, Barkin JS: Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol 2009, 15:1554-1580.
• [3]Reichardt C, Chaberny IF, Kola A, Mattner F, Vonberg RP, Gastmeier P: [Dramatic increase of Clostridium difficile-associated diarrhea in Germany: has the new strain PCR-ribotype 027 already reached us?]. Dtsch Med Wochenschr 2007, 132:223-228.
• [4]Koh TH, Tan AL, Tan ML, Wang G, Song KP: Epidemiology of Clostridium difficile infection in a large teaching hospital in Singapore. Pathology 2007, 39:438-442.
• [5]DuPont HL, Garey K, Caeiro J, Jiang Z: New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control. Curr Opin Infect Dis 2008, 21:500-507.
• [6]Kuijper EJ, Barbut F, Brazier JS, Kleinkauf N, Eckmanns T, Lambert ML, Drudy D, Fitzpatrick F, Wiuff C, Brown DJ, Coia JE, Pituch H, Reichert P, Even J, Mossong J, Widmer AF, Olsen KE, Allerberger F, Notermans DW, Delmée M, Coignard B, Wilcox M, Patel B, Frei R, Nagy E, Bouza E, Marin M, Akerlund T, Virolainen-Julkunen A, Lyytikäinen O, Kotila S, Ingebretsen A, Smyth B, Rooney P, Poxton IR, Monnet DL: Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill 2008., 13
• [7]Thomas C, Stevenson M, Riley TV: Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 2003, 51:1339-1350.
• [8]Kaier K, Frank U: Relationship between antibiotic consumption and Clostridium difficile-associated diarrhea: an epidemiological note. Antimicrob Agents Chemother 2009, 53:4574-4575.
• [9]Kim JW, Lee KL, Jeong JB, Kim BG, Shin S, Kim JS, Jung HC, Song IS: Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea. World J Gastroenterol 2010, 16:3573-3577.
• [10]Aseeri M, Schroeder T, Kramer J, Zackula R: Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008, 103:2308-2313.
• [11]Vesta KS, Wells PG, Gentry CA, Stipek WJ: Specific risk factors for Clostridium difficile-associated diarrhea: a prospective, multicenter, case control evaluation. Am J Infect Control 2005, 33:469-472.
• [12]Gifford AH, Kirkland KB: Risk factors for Clostridium difficile-associated diarrhea on an adult hematology-oncology ward. Eur J Clin Microbiol Infect Dis 2006, 25:751-755.
• [13]Blot E, Escande M, Besson D, Barbut F, Granpeix C, Asselain B, Falcou MC, Pouillart P: Outbreak of Clostridium difficile-related diarrhoea in an adult oncology unit: risk factors and microbiological characteristics. J Hosp Infect 2003, 53:187-192.
• [14]Hornbuckle K, Chak A, Lazarus HM, Cooper GS, Kutteh LA, Gucalp R, Carlisle PS, Sparano J, Parker P, Salata RA: Determination and validation of a predictive model for Clostridium difficile diarrhea in hospitalized oncology patients. Ann Oncol 1998, 9:307-311.
• [15]Tai E, Richardson LC, Townsend J, Howard E, McDonald LC: Clostridium difficile Infection Among Children With Cancer. Pediatr Infect Dis J 2011, 30:610-612.
• [16]Patyánik M, Nemeskéri C, Póti Z, Sinkó D, Pesznyák C, Király R, Kois R, Mayer A: Concomitant radiochemotherapy of cervical cancer: is it justified to reduce the dosage of cisplatin? Strahlenther Onkol 2009, 185:582-587.
• [17]Bernier J: Current state-of-the-art for concurrent chemoradiation. Semin Radiat Oncol 2009, 19:3-10.
• [18]Wolff HA, Bosch J, Jung K, Overbeck T, Hennies S, Matthias C, Hess CF, Roedel RM, Christiansen H: High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer. Strahlenther Onkol 2010, 186:262-268.
• [19]Steinmann D, Cerny B, Karstens JH, Bremer M: Chemoradiotherapy with weekly cisplatin 40 mg/m(2) in 103 head-and-neck cancer patients: a cumulative dose-effect analysis. Strahlenther Onkol 2009, 185:682-688.
• [20]Manikantan K, Khode S, Sayed SI, Roe J, Nutting CM, Rhys-Evans P, Harrington KJ, Kazi R: Dysphagia in head and neck cancer. Cancer Treat Rev 2009, 35:724-732.
• [21]Wurstbauer K, Merz F, Sedlmayer F: Amphotericin B lozengers: prophylaxis for esophagitis in thoracic radiotherapy: a prospective study. Strahlenther Onkol 2009, 185:512-516.
• [22]Semrau S, Waldfahrer F, Lell M, Linke R, Klautke G, Kuwert T, Uder M, Iro H, Fietkau R: Feasibility, Toxicity, and Efficacy of Short Induction Chemotherapy of Docetaxel Plus Cisplatin or Carboplatin (TP) Followed by Concurrent Chemoradio - therapy for Organ Preservation in Advanced Cancer of the Hypopharynx, Larynx, and Base of Tongue. Early Results. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft ... [et al] 2010.
• [23]Anand A, Bashey B, Mir T, Glatt AE: Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. Am J Gastroenterol 1994, 89:519-523.
• [24]Crabtree T, Aitchison D, Meyers BF, Tymkew H, Smith JR, Guthrie TJ, Munfakh N, Moon MR, Pasque MK, Lawton J, Moazami N, Damiano RJ Jr: Clostridium difficile in cardiac surgery: risk factors and impact on postoperative outcome. Ann Thorac Surg 2007, 83:1396-1402.
• [25]Yamazawa K, Kanno H, Seki K, Kuzuta T, Matsui H, Sekiya S: Life-threatening Clostridium difficile-associated diarrhea induced by paclitaxel-carboplatin combination chemotherapy. Acta Obstet Gynecol Scand 2001, 80:768-769.
• [26]Resnik E, Lefevre CA: Fulminant Clostridium difficile colitis associated with paclitaxel and carboplatin chemotherapy. Int J Gynecol Cancer 1999, 9:512-514.
• [27]Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW: Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 2010, 74:309-318.
• [28]Heinlen L, Ballard JD: Clostridium difficile infection. Am J Med Sci 2010, 340:247-252.
• [29]Fraunholz I, Rabeneck D, Weiss C, Rödel C: Combined-modality treatment for anal cancer: current strategies and future directions. Strahlenther Onkol 2010, 186:361-366.
• [30]Platteaux N, Dirix P, Vanstraelen B, Nuyts S: Outcome after Re-Irradiation of Head and Neck Cancer Patients. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft ... [et al] 2010.
• [31]Wolf M, Zehentmayr F, Niyazi M, Ganswindt U, Haimerl W, Schmidt M, Hölzel D, Belka C: Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer. Strahlenther Onkol 2010, 186:374-381.
• [32]Huguenin P, Glanzmann C, Taussky D, Lütolf UM, Schmid S, Moe K: Hyperfractionated radiotherapy and simultaneous cisplatin for stage-III and -IV carcinomas of the head and neck. Long-term results including functional outcome. Strahlenther Onkol 1998, 174:397-402.
• [33]Bliss DZ, Johnson S, Savik K, Clabots CR, Willard K, Gerding DN: Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med 1998, 129:1012-1019.
• [34]O'Keefe SJD: Tube feeding, the microbiota, and Clostridium difficile infection. World J Gastroenterol 2010, 16:139-142.
• [35]Beckmann GK, Hoppe F, Pfreundner L, Flentje MP: Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head Neck 2005, 27:36-43.
• [36]Chopra T, Alangaden GJ, Chandrasekar P: Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther 2010, 8:1113-1119.
• [37]Leung S, Metzger BS, Currie BP: Incidence of Clostridium difficile infection in patients with acute leukemia and lymphoma after allogeneic hematopoietic stem cell transplantation. Infect Control Hosp Epidemiol 2010, 31:313-315.
• [38]Bese NS, Hendry J, Jeremic B: Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys 2007, 68:654-661.
• [39]van den Bogaert W, van der Leest A, Rijnders A, Delaere P, Thames H, van der Schueren E: Does tumor control decrease by prolonging overall treatment time or interrupting treatment in laryngeal cancer? Radiother Oncol 1995, 36:177-182.
• [40]Maciejewski B, Preuss-Bayer G, Trott KR: The influence of the number of fractions and of overall treatment time on local control and late complication rate in squamous cell carcinoma of the larynx. Int J Radiat Oncol Biol Phys 1983, 9:321-328.
• [41]Machtay M, Hsu C, Komaki R, Sause WT, Swann RS, Langer CJ, Byhardt RW, Curran WJ: Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys 2005, 63:667-671.
• [42]Pignon J, Le Maître A, Maillard E, Bourhis J: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009, 92:4-14.
• [43]Foote: The Importance of Planned Dose of Chemotherapy on Time: Do We Need to Change Our Clinical Practice? Oncologist 1998, 3:365-368.
• [44]Ho KF, Swindell R, Brammer CV: Dose intensity comparison between weekly and 3-weekly Cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: a retrospective comparison from New Cross Hospital, Wolverhampton, UK. Acta Oncol 2008, 47:1513-1518.
• [45]Pépin J, Saheb N, Coulombe M, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L: Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005, 41:1254-1260.
• [46]Miller K, Fraser T: Q: What is the role of probiotics in the treatment of acute Clostridium difficile-associated diarrhea? Cleve Clin J Med 2009, 76:391-392.
• [47]Pillai A, Nelson R: Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008, CD004611.
• [48]Segarra-Newnham M: Probiotics for Clostridium difficile-associated diarrhea: focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii. Ann Pharmacother 2007, 41:1212-1221.
• [49]Monaghan T, Boswell T, Mahida YR: Recent advances in Clostridium difficile-associated disease. Gut 2008, 57:850-860.